{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:10:03Z","timestamp":1744355403031,"version":"3.40.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 65-year-old woman with a history of ductal mammary carcinoma and recent autonomic dysfunction underwent a Rb-82 chloride (RbCl) cardiac PET\/CT scan that showed no ischemia or scarring, but significantly reduced myocardial flow reserve (MFR) (global: 1.5) and a CAC-Score of 0. The patient\u2019s chemotherapy history (paclitaxel, carboplatin, epirubicin, pembrolizumab 2 years before) with elevated Troponin T and NT-pro-BNP levels at that time, and now reduced MFR with 0 CAC suggests cancer-therapy-related cardiotoxicity. An important differential diagnosis to the more common CAD-associated microvascular disease. Furthermore, tumor recurrence with a PET-avid lymph node metastasis was found additionally.<\/jats:p>","DOI":"10.1007\/s10554-024-03315-4","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:07:44Z","timestamp":1736363264000},"page":"817-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiotoxicity as important differential diagnosis for reduced myocardial blood flow during Rubidium cardiac PET\/CT"],"prefix":"10.1007","volume":"41","author":[{"given":"Sabin G.","family":"Pop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"H\u00e4gler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander W.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"3315_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/MNM.0b013e3283440dcb","volume":"32","author":"S Mirpour","year":"2011","unstructured":"Mirpour S, Khandani AH (2011) Extracardiac abnormalities on rubidium-82 cardiac positron emission tomography\/computed tomography. Nucl Med Commun 32:260\u2013264","journal-title":"Nucl Med Commun"},{"key":"3315_CR2","doi-asserted-by":"publisher","first-page":"912329","DOI":"10.3389\/fcvm.2022.912329","volume":"9","author":"W Huang","year":"2022","unstructured":"Huang W, Xu R, Zhou B et al (2022) Clinical manifestations, monitoring, and prognosis: a review of Cardiotoxicity after Antitumor Strategy. Front Cardiovasc Med 9:912329","journal-title":"Front Cardiovasc Med"},{"doi-asserted-by":"publisher","unstructured":"Viswanathan T, Lang CC, Petty RD et al (2021) Cardiotoxicity and Chemotherapy-The Role of Precision Medicine. Diseases [Internet]. ;9. Available from: https:\/\/doi.org\/10.3390\/diseases9040090","key":"3315_CR3","DOI":"10.3390\/diseases9040090"},{"key":"3315_CR4","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.xcrm.2021.100216","volume":"2","author":"P Mamoshina","year":"2021","unstructured":"Mamoshina P, Rodriguez B, Bueno-Orovio A (2021) Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med 2:100216","journal-title":"Cell Rep Med"},{"key":"3315_CR5","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/ejhf.1215","volume":"20","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Patel RB, Butler J et al (2018) Epirubicin and long-term heart failure risk in breast cancer survivors. Eur J Heart Fail 20:1454\u20131456","journal-title":"Eur J Heart Fail"},{"key":"3315_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front Cardiovasc Med 7:26","journal-title":"Front Cardiovasc Med"},{"key":"3315_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/eurjpc\/zwac229","volume":"30","author":"K Jin","year":"2022","unstructured":"Jin K (2022) Does coronary microvascular dysfunction have a role in cardiovascular oncology? Eur J Prev Cardiol Oxf Acad 30:206\u2013208","journal-title":"Eur J Prev Cardiol Oxf Acad"},{"key":"3315_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurjpc\/zwac184","volume":"30","author":"N Rajai","year":"2023","unstructured":"Rajai N, Ahmad A, Toya T et al (2023) Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease. Eur J Prev Cardiol 30:209\u2013216","journal-title":"Eur J Prev Cardiol"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-024-03315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-024-03315-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-024-03315-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:16:37Z","timestamp":1744172197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-024-03315-4"}},"subtitle":["Cardiotoxicity in Rubidium PET\/CT"],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3315"],"URL":"https:\/\/doi.org\/10.1007\/s10554-024-03315-4","relation":{},"ISSN":["1875-8312"],"issn-type":[{"type":"electronic","value":"1875-8312"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}